TY - JOUR A1 - Steinmann, Diana A1 - Paelecke-Habermann, Yvonne A1 - Geinitz, Hans A1 - Aschoff, Raimund A1 - Bayerl, Anja A1 - Bölling, Tobias A1 - Bosch, Elisabeth A1 - Bruns, Frank A1 - Eichenseder-Seiss, Ute A1 - Gerstein, Johanna A1 - Gharbi, Nadine A1 - Hagg, Juliane A1 - Hipp, Matthias A1 - Kleff, Irmgard A1 - Müller, Axel A1 - Schäfer, Christof A1 - Schleicher, Ursula A1 - Sehlen, Susanne A1 - Theodorou, Marilena A1 - Wypior, Hans-Joachim A1 - Zehentmayr, Franz A1 - van Oorschot, Birgitt A1 - Vordermark, Dirk T1 - Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases JF - BMC Cancer N2 - Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 %) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months. Results: At 3 months, 88/142 (62 %) survived. Nine patients were not able to be followed up. 62 patients (70.5 % of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 % vs. 37 %), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival. Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information. KW - breast cancer KW - brain tumours KW - survival KW - validation KW - symptoms KW - EORTC-QLQ-C15-PAL KW - EORTC-BN20 KW - whole-brain radiotherapy KW - partitioning analysis RPA KW - cancer patients KW - lung cancer KW - prognostic index KW - radiation oncology KW - clinical trials Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135254 VL - 12 IS - 283 ER - TY - JOUR A1 - Alepee, Natalie A1 - Bahinski, Anthony A1 - Daneshian, Mardas A1 - De Weyer, Bart A1 - Fritsche, Ellen A1 - Goldberg, Alan A1 - Hansmann, Jan A1 - Hartung, Thomas A1 - Haycock, John A1 - Hogberg, Helena T. A1 - Hoelting, Lisa A1 - Kelm, Jens M. A1 - Kadereit, Suzanne A1 - McVey, Emily A1 - Landsiedel, Robert A1 - Leist, Marcel A1 - Lübberstedt, Marc A1 - Noor, Fozia A1 - Pellevoisin, Christian A1 - Petersohn, Dirk A1 - Pfannenbecker, Uwe A1 - Reisinger, Kerstin A1 - Ramirez, Tzutzuy A1 - Rothen-Rutishauser, Barbara A1 - Schäfer-Korting, Monika A1 - Zeilinger, Katrin A1 - Zurich, Marie-Gabriele T1 - State-of-the-Art of 3D Cultures (Organs-on-a-Chip) in Safety Testing and Pathophysiology JF - ALTEX - Alternatives to Animal Experimentation N2 - Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs liver, lung, skin, brain are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing. KW - 3D models KW - organotypic KW - organ-on-a-chip KW - multicellular tumor spheroids KW - primary human hepatocytes KW - embryonic stem cell KW - reconstructed human epidermis KW - in-vitro models KW - full thickness skin KW - necrosis-factor-alpha KW - metabolic flux analysis KW - long-term KW - human liver cells Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117826 VL - 31 IS - 4 ER - TY - THES A1 - Schäfer, Dirk T1 - Globale Selbstlokalisation autonomer mobiler Roboter - Ein Schlüsselproblem der Service-Robotik T1 - The global self-localisation problem - a key problem in the field of service robotics N2 - Die Dissertation behandelt die Problemstellung der globalen Selbstlokalisation autonomer mobiler Roboter, welche folgendermaßen beschrieben werden kann: Ein mobiler Roboter, eingesetzt in einem Gebäude, kann unter Umständen das Wissen über seinen Standort verlieren. Man geht nun davon aus, dass dem Roboter eine Gebäudekarte als Modell zur Verfügung steht. Mit Hilfe eines Laser-Entfernungsmessers kann das mobile Gerät neue Informationen aufnehmen und damit bei korrekter Zuordnung zur Modellkarte geeignete hypothetische Standorte ermitteln. In der Regel werden diese Positionen aber mehrdeutig sein. Indem sich der Roboter intelligent in seiner Einsatzumgebung bewegt, kann er die ursprünglichen Sensordaten verifizieren und ermittelt im besten Fall seine tatsächliche Position.Für diese Problemstellung wird ein neuer Lösungsansatz in Theorie und Praxis präsentiert, welcher die jeweils aktuelle lokale Karte und damit alle Sensordaten mittels feature-basierter Matchingverfahren auf das Modell der Umgebung abbildet. Ein Explorationsalgorithmus bewegt den Roboter während der Bewegungsphase autonom zu Sensorpunkten, welche neue Informationen bereitstellen. Während der Bewegungsphase werden dabei die bisherigen hypothetischen Positionen bestärkt oder geschwächt, sodaß nach kurzer Zeit eine dominante Position, die tatsächliche Roboterposition,übrigbleibt. N2 - This thesis is dealing with the global self-localisation problem, which is known to be one of the hardest problems among autonomous mobile systems. The problem can be described as follows: A mobile robot agent has a map of the environment but does not know its position. It is equipped with ultransonic sensors and a laser range finder as main sensor. The goal of the robot agent is to recognize its true position within the environment.The level of complexity of this task increases with the size and also with the level of symmetry of the indoor environment. To cope with the problem a new approach will be presented in this thesis using state of the art map building and exploration algorithms as well as feature based localisation methods. Decomposition of the global map into a number of submaps, informative feature selection and multiple submap localisation queries ensure the road of success. The capability of the approach to global self-localising the robot is pointed out by several practical studies. KW - Mobiler Roboter KW - Autonomer Roboter KW - Lokalisation KW - Globale Selbstlokalisation KW - Mobile Roboter KW - Kartierung KW - Feature-Matching KW - Gllobal self-localisation KW - mobile robots KW - slam KW - feature-matching Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-7601 ER - TY - JOUR A1 - Jobs, Alexander A1 - Vonthein, Reinhard A1 - König, Inke R. A1 - Schäfer, Jane A1 - Nauck, Matthias A1 - Haag, Svenja A1 - Fichera, Carlo Federico A1 - Stiermaier, Thomas A1 - Ledwoch, Jakob A1 - Schneider, Alisa A1 - Valentova, Miroslava A1 - von Haehling, Stephan A1 - Störk, Stefan A1 - Westermann, Dirk A1 - Lenz, Tobias A1 - Arnold, Natalie A1 - Edelmann, Frank A1 - Seppelt, Philipp A1 - Felix, Stephan A1 - Lutz, Matthias A1 - Hedwig, Felix A1 - Borggrefe, Martin A1 - Scherer, Clemens A1 - Desch, Steffen A1 - Thiele, Holger T1 - Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA‐ADHF‐DZHK10 trial JF - ESC Heart Failure N2 - Aims Treating patients with acute decompensated heart failure (ADHF) presenting with volume overload is a common task. However, optimal guidance of decongesting therapy and treatment targets are not well defined. The inferior vena cava (IVC) diameter and its collapsibility can be used to estimate right atrial pressure, which is a measure of right‐sided haemodynamic congestion. The CAVA‐ADHF‐DZHK10 trial is designed to test the hypothesis that ultrasound assessment of the IVC in addition to clinical assessment improves decongestion as compared with clinical assessment alone. Methods and results CAVA‐ADHF‐DZHK10 is a randomized, controlled, patient‐blinded, multicentre, parallel‐group trial randomly assigning 388 patients with ADHF to either decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment or clinical assessment alone. IVC ultrasound will be performed daily between baseline and hospital discharge in all patients. However, ultrasound results will only be reported to treating physicians in the intervention group. Treatment target is relief of congestion‐related signs and symptoms in both groups with the additional goal to reduce the IVC diameter ≤21 mm and increase IVC collapsibility >50% in the intervention group. The primary endpoint is change in N‐terminal pro‐brain natriuretic peptide from baseline to hospital discharge. Secondary endpoints evaluate feasibility, efficacy of decongestion on other scales, and the impact of the intervention on clinical endpoints. Conclusions CAVA‐ADHF‐DZHK10 will investigate whether IVC ultrasound supplementing clinical assessment improves decongestion in patients admitted for ADHF. KW - acute decompensated heart failure KW - inferior vena cava KW - congestion KW - NT‐proBNP KW - ultrasound Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-212692 VL - 7 IS - 3 SP - 973 EP - 983 ER -